Schedules of Nab-Paclitaxel: evaluation of different schedules of nab-paclitaxel for metastatic breast cancer
This trial is coordinated and sponsored by the International Breast Cancer Study Group (IBCSG) under the umbrella of the Breast International Group.
Pharmaceutical partner: Celgene
Funding: Celgene grant
More To Explore
DECRESCENDO BIG 19-02 De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Share